Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.75 |
| ▸ | PGR | P06401 | 3/20 | 0.75 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | SHBG | P04278 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Phosphoric Acid SCHEMBL21313286 | 0.96 | HIF1A (0.81) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone Phosphoric Acid SCHEMBL42271 | 0.93 | HIF1A (0.77) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone Phosphoric Acid SCHEMBL19459282 | 0.93 | HIF1A (0.77) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone Phosphoric Acid SCHEMBL1761098 | 0.93 | HIF1A (0.77) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone Phosphoric Acid SCHEMBL21647387 | 0.92 | HIF1A (0.75) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone SCHEMBL3105433 | 0.92 | HIF1A (0.88) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone SCHEMBL364232 | 0.92 | HIF1A (0.88) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone SCHEMBL5578673 | 0.92 | HIF1A (0.88) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone SCHEMBL41084 | 0.92 | HIF1A (0.88) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 | |
| Hydrocortisone SCHEMBL2679010 | 0.92 | HIF1A (0.88) | HIF1ANFKB1PMP22TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010344-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021030142-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | ACACB, ACACA, ACAT2 | NR3C1 2327/4885HIF1A 3406/4885NFKB1 1266/4885 |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | NR3C1 2175/4885HIF1A 3010/4885NFKB1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.